StoxDr. Reddy's Laboratories vs Cipla: share price & financials comparison
NSE: DRREDDY vs CIPLA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Reddy's Laboratories vs Cipla at a glance
Dr. Reddy's Laboratories (DRREDDY) has a market capitalisation of ₹1,14,646 Cr, against ₹1,13,988 Cr for Cipla (CIPLA). Over the past year Dr. Reddy's Laboratories has returned +9.8%, compared with -10.8% for Cipla. On valuation, Cipla trades at a lower P/E of 39.3 versus 40.9. Cipla earns a higher return on equity (8.2% vs 7.2%). Dr. Reddy's Laboratories comes out ahead on size, growth, momentum and technicals. Cipla comes out ahead on valuation, profitability and financial health. Across the scored metrics below, Dr. Reddy's Laboratories leads on 10 and Cipla on 8. On StoxGud's 10-point checklist, Dr. Reddy's Laboratories scores 5/10 and Cipla scores 6/10.
| Metric | Dr. Reddy's Laboratories | Cipla |
|---|---|---|
| Size | ||
| Market cap | ₹1,14,646 Cr | ₹1,13,988 Cr |
| Revenue (latest FY) | ₹33,700 Cr | ₹28,163 Cr |
| Net profit (latest FY) | ₹4,196 Cr | ₹3,879 Cr |
| Valuation | ||
| P/E | 40.9 | 39.3 |
| P/B | 2.95 | 3.22 |
| Dividend yield | 0.58% | 1.13% |
| Profitability | ||
| Return on equity | 7.2% | 8.2% |
| Net profit margin | 8.5% | 10.3% |
| Operating margin | 14.7% | 17.0% |
| Growth | ||
| Revenue growth (YoY) | -1.5% | -2.4% |
| Net profit growth (YoY) | -31.3% | -35.1% |
| Revenue CAGR (multi-year) | +12.1% | +8.0% |
| Financial health | ||
| Debt to equity | 0.15 | 0.01 |
| Momentum | ||
| 1-month return | +14.1% | +6.3% |
| 1-year return | +9.8% | -10.8% |
| 3-year CAGR | +8.7% | +5.4% |
| 5-year CAGR | +7.5% | +9.1% |
| 10-year CAGR | +8.3% | +10.0% |
| Distance from 52W high | -0.2% | -8.4% |
| Technicals | ||
| RSI (14) | 84 | 82 |
| Price vs 200-day avg | +9.9% | +3.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Reddy's Laboratories | Cipla |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✗ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 5/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Reddy's Laboratories or Cipla?
Dr. Reddy's Laboratories has a market cap of ₹1,14,646 Cr and Cipla has a market cap of ₹1,13,988 Cr as of 06 Nov 2026.
Which has a lower P/E, Dr. Reddy's Laboratories or Cipla?
Cipla has the lower P/E: Dr. Reddy's Laboratories trades at 40.9 and Cipla at 39.3.
Which gave better returns in the last year, Dr. Reddy's Laboratories or Cipla?
Dr. Reddy's Laboratories did better: Dr. Reddy's Laboratories returned +9.8% and Cipla returned -10.8% over one year.
Is Dr. Reddy's Laboratories or Cipla a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Dr. Reddy's Laboratories scores 5/10 and Cipla scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.